Chelsea Therapeutics receives approval to use Northera capsules from US Food and Drug Administration.
M2 PHARMA-February 20, 2014-Chelsea Therapeutics receives approval to use Northera capsules from US Food and Drug Administration
(C)2014 M2 COMMUNICATIONS
Chelsea Therapeutics (Nasdaq:CHTP), a biopharmaceutical company, has received approval to use Northera capsules (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension, from the United States Food and Drug Administration, it was reported yesterday.
The drug is the first and only therapy approved by the United States Food and Drug Administration that indicated symptomatic benefit in patients with neurogenic orthostatic hypotension.
The United States Food and Drug Administration is approving the drug under the accelerated approval programme, which enables for conditional approval of a drug to treat a serious disease based on clinical data showing that the drug has an effect on an intermediate clinical measure.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 20, 2014|
|Previous Article:||DKSH Business Unit Healthcare signs regional agreement with Cheplapharm.|
|Next Article:||MicroBiome reports top-line results from clinical trial of microbiome modulator NM504.|